Viewing entries tagged
News

VAX-IDTM by Novosanis to be used in Phase 1 vaccination trial by German biopharmaceutical company ImevaX

Wijnegem, Belgium, July 26th 2016: Novosanis announced today their collaboration with ImevaX, a biopharmaceutical company based in Munich, Germany. ImevaX developed a vaccine against the pathogen Helicobacter pylori (H. pylori) that can cause chronic stomach sores and ulcers potentially leading to gastric cancer. Novosanis will supply the VAX-ID™ device that allows for a standardized and accurate injection of the vaccine for their clinical trials.